Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Blueprint Medicines, Proteovant Collaboration For Protein Degrader Therapies

Blueprint Medicines Corporation (NASDAQ:BPMC) and Proteovant Therapeutics have entered a strategic collaboration for targeted protein degrader therapies

  • The collaboration will bring Proteovant's Artificial Intelligence (AI)-enhanced targeted protein degradation (TPD) platform and Blueprint Medicine's precision medicine expertise to discover novel targeted protein degraders. 
  • The companies will jointly research important targets and advance up to two novel protein degrader therapies into development candidates. 
  • Proteovant's exclusive partner for TPD, VantAI, will deploy its leading AI technologies for degrader generation and optimization.
  • Upon designation of a clinical development candidate, Blueprint Medicines has the exclusive option to develop and commercialize products resulting from the collaboration. 
  • Proteovant has the option to co-develop and co-commercialize the second of the two Blueprint Medicines-optioned programs in the U.S.
  • Proteovant will receive a $20 million upfront payment and be eligible for an additional $632 million in milestone payments plus tiered royalties from mid-to high-single digits on net sales on the first two programs targets.
  • Price Action: BPMC shares are down 0.16% at $62.08 during the market session on the last check Monday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.